AiCure's patented artificial intelligence technology visually confirms medication ingestion on any smartphone. In addition to pharmaceutical industry and academic collaborators, AiCure has received funding from the National Institutes of Health, including grant numbers 271201200020C-0-0-1, 271201300036C-0-0-1, 1R43RR032224-01A1, 9R44TR000873-02, 5 R44 TR000873 03, 1R43TR000190-01, and a sub-award on grant number 1R01MH109320-01. AiCure has an extensive IP portfolio, comprising 12 awarded and 45 pending US and global patents.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/11/16 | $12,250,000 | Series A |
Biomatics Capital New Leaf Venture Partners Pritzker Group Venture Capital Tribeca Venture Partners | undisclosed |
| 11/07/19 | $24,500,000 | Series C |
Accelmed Growth Partners Asahi Kasei Baird Capital Biomatics Capital New Leaf Venture Partners Palisades Growth Capital  Pritzker Group Venture Capital Silicon Valley Bank SingTel Innov8 SpringRock Ventures Tribeca Venture Partners | undisclosed |
| 01/23/24 | undisclosed | Venture Debt & Equity |
